Empowered Patient Podcast

SMART Opioids Mitigate Risks of Opioid Abuse for Safer Pain Management with Greg Sturmer and Tom Jenkins Elysium Therapeutics

Informações:

Sinopse

Greg Sturmer, CEO and Co-Founder, and Tom Jenkins, Chief Science Officer and Co-Founder of Elysium Therapeutics, talk about their SMART Opioid O2P, which aims to address the risks of taking opioids while still delivering the analgesic efficacy of opioids.  The compound is designed to be resistant to abuse through snorting or injections and includes a trypsin inhibitor that prevents the release of the opioid when multiple pills are ingested. Elysium is also developing SOOPR, an opioid overdose rescue medication that has a longer duration of action to counteract the longer-lasting effects of synthetic opioids such as Fentanyl.   Greg explains, "When we talk about our SMART opioids for pain, SMART stands for Safer Medicines that Alleviate Risks and Trauma. Our space is led by our O2P hydrocodone product candidate, and O2P stands for oral overdose protection." "So what O2P hydrocodone is designed to do is mitigate those major risks associated with existing prescription opioids, but doing so without sacrificing